Are Antiphospholipid Antibodies an Independent Risk Factor for Atherosclerosis?

Abstract

The purpose of this study was to check whether antiphospholipid antibodies (aPL) could be an independent risk factor for atherosclerosis. Eighty-five subjects were studied: 45 with primitive antiphospholipid antibody syndrome and 40 controls affected by deep vein thrombosis secondary to known causes. The two groups were homogeneous for age, sex, and risk factors for atherosclerosis. All the subjects submitted to echo-color doppler of the carotid arteries, femoral arteries, and abdominal aorta. The cases were then subdivided into three subgroups on the basis of the positivity to the three subpopulations of aPL. Results demonstrate that there is no correlation between aPL and atherosclerosis. The different positivity to aPL does not modify this conclusion.

Keywords

Antiphospholipid antibodies Atherosclerosis

References

1. Roubey RA . Antibodies to phospholipid-binding plasma proteins. A new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood 1944;84:2854-2854.

2. Love PE , Santoro SA . Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112:682-682.

3. Harris EN , Gharavi AE , Hughes GRV . Antiphospholipid antibodies. Clin Rheum Dis 1985;11:591-591.

4. Hughes GRV , Asherson RA , Gharavi AE . The anticardiolipin syndrome. J Rheumatol 1986;13:486-486.

5. Feinstein DI , Rappaport SI . Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972; 1:75-75.

6. Shapiro SS , Thigarajan P . Lupus anticoagulants. In: Spaet TH , ed. Progress in Hemostasis and Thrombosis. New York: Grune and Stratton, 1982;6:263-263.

7. Lechner K . Acquired inhibitors in nonhemophilic patients. Haemostasis 1969;3:65-65.

8. Schleider MA , Nachman RL , Jaffee EA , Coleman M . A clinical study of the lupus anticoagulant. Blood 1976;48:499-499.

9. Frick PG . Acquired circulating anticoagulants in systemic collagen disease. Autoimmune thromboplastin deficiency. Blood 1955;10:691-691.

10.

10. Regan MG , Lackner H , Karpatkin S . Platelet function and coagulation profile in lupus erythematosus. Studies in 50 patients. Ann Intern Med 1974;81:462-462.

11.

11. Lee SL , Sanders M . A disorder of blood coagulation in systemic lupus erythematosus. J Clin Invest 1955;34:1814-1814.

12.

12. Galli M , Confurius P , Maassen C , et al. Anticardiolipin antibodies directed not to cardiolipin but to a plasma cofactor. Lancet 1990;335:1544-1544.

13.

13. Oosting JD , Derksen RHWH , Bobbink IWG , et al. Antiphospholipid antibodies directed against a combination phospholipids with prothrombin, protein C or protein S: An explanation for their pathogenetic mechanism? Blood 1993;81:2618-2618.

14.

14. Puurunen M , Manttari M , Mannine V , Vaarala O Antibodies to phospholipid-binding proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996;80:16-16.

15.

15. Palinsky W , Yla-Herttuals S , Rosenfeld ME . Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990;10:325-325.

16.

16. Simioni P , Prandoni P , Zanon E , et al. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost 1996;76(2):187-187.

17.

17. Branch DW , Andres R , Digre KB , et al. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 1989;73:541-541.

18.

18. Hughes GRV . Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 1983;287:1088-1088.

19.

19. Vermylen J , Blockmans D , Spitz B , Deckmin H . Thrombosis and immune disorders. Clin Haematol 1986;15:1-1.

20.

20. Asherson RA , Harris EN . Anticardiolipin antibodies: Clinical associations. Postgrad Med J 1986;62:1081-1081.

21.

21. Alarcon-Segovia G , Sanchez-Guerrero J . Primary antiphospholipid syndrome. Rheumatology 1989;16:482-482.

22.

22. Asherson RA . A “primary” antiphospholipid syndrome? J Rheumatol 1988;15:1742-1742.

23.

23. Harris EN , Asherson RA , Hughes GRV . Antiphospholipid antibodies autoantibodies with a difference. Ann Rev Med 1988;39:261-261.

24.

24. Catteral RD . Biological false positive reactions and systemic disease. In: Walker G , ed. Ninth Symposium on Advanced Medicine. London: Pitman Medical, 1973;97-97.

25.

25. Zarrabi MH , Zucker S , Miller F , et al. Immunologic and coagulation disorders in chlorpromazine treated patients. Ann Intern Med 1979;91:194-194.

26.

26. Canoso RT , Sise HS . Chlorpromazine-induced lupus anticoagulant and associated immunological abnormalities. Am J Hematol 1982;13:121-121.

27.

27. Libby P , Hansson GK . Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest 1991;64:5-5.

28.

28. Wick G , Schett G , Amberger A , et al. Is atherosclerosis an immunologically mediated disease? Immunol Today 1995;16:27-27.

29.

29. Lecerf V , Alhenc-Gelas M , Laurian C , et al. Antiphospholipid antibodies and atherosclerosis. Am J Med 1992;92:575-575.

30.

30. Witztum JL . The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-793.

31.

31. Sletnes KE , Smith P , Abdelnoor M , Arriesen F . Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992;339:451-451.

32.

32. Maaravi Y , Raz E , Gilon D , Rubinow A . Cerebrovascular accident and myocardial infarction associated with anticardiolipin antibodies in a young woman with systemic lupus erythematosus. Ann Rhem Dis 1989;48:853-853.

33.

33. Salonen JT , Yla-Herttuala S , Yamamoto R , et al. Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-883.

34.

34. Harris EN , Gharavi AE , Patel SP , Hughes GRV . Evaluation of the anti-cardiolipin antibody test: Report of a standardisation workshop held April 4, 1986. Clin Exp Immunol 1987;68:215-215.

35.

35. Bruce IN , Burns RJ , Gladman DD , Urowitz MB . SPECT dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. J Rheumatol 1998;25 (Suppl.52):72-72.

36.

36. Manzi S , Selzer F , Sutton-Tyrrell K , et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheumatol J 1999;42:51-51.

37.

37. Virella G , Virella I , Leman RB , et al. Anti-oxidised lowdensity lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 1993;23:95-95.

38.

38. Hamsten A , Bjorkholm M , Norber R , et al. Antibodies to cardiolipin in young survivors of myocardial infarction: An association with recurrent cardiovascular events. Lancet 1986;1:113-113.

39.

39. Stevens SL , Hilgarth K , Ryan US , et al. The synergistic effect of hypercholesteremia and mechanical injury on intimal hyperplasia. Ann Vasc Surg 1992;6:55-55.

40.

40. Kannel WB , Wolf PA , McGee DL , et al. Systolic blood pressure, arterial rigidity and risk of stroke. JAMA 1981;245:1225-1225.

41.

41. Kawamori R , Yamasaki Y , Matsushima H , et al. Prevalence of carotid atherosclerosis in diabetic patients: Ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care 1992;15:1290-1290.

42.

42. Dempsey RJ , Moore RW . Amount of smoking independently predicts carotid artery atherosclerosis severity. Stroke 1992;23:693-693.

43.

43. George J . Differential effects of anti-,B2 GP1 antibodies endothelial cells and on the manifestations of experimental phospholipid syndrome. Circulation 1998;97:900-900.

44.

44. George J , Afek A , Gilburd S , et al. Atherosclerosis in LDL receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus 1997;6:723-723.

45.

45. George J , Afek A , Gilburd S , et al. Induction of early atherosclerosis in LDL receptor deficient mice immunized with beta2 glycoprotein I. Circulation 1998;15:1108-1108.

46.

46. Ross B . Atherosclerosis: an inflammatory disease. N Engl J Med 1990;340:115-115.

47.

47. Urowitz MB , Gladman DD . Accelerated atheroma in lupusbackground. Lupus 2000;9:161-161.

48.

48. Howite NT , Samuel P , Ginzler E , Jacobson MS . Dyslipoproteinemias in pediatric systemic lupus erythematosus. Arthritis Rheum 1988;31:859-859.

49.

49. Borba EF , Bonfa E . Dyslipoproteinemias in systemic lupus erythematosus influence of disease activity and anticardiolipin antibodies. Lupus 1997;6:533-533.

50.

50. Petri M , Rubenoff R , Dallal GE . Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-1120.

51.

51. Kannel WB , D'Agostino RB , Belanger AJ . Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 1992;2:457-457.

52.

52. Hamsten A , de Faire U , Walldius G . Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;2:3-3.

53.

53. MacGregora M . Fasting lipids and anticardiolipin antibodies are factors for vascular disease in systemic lupus erythematosus. Rheum Dis 1992;51 152-152.

54.

54. Borba EF , Santos RD , Bonfa E , et al. Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol 1994;21:220-220.

55.

55. Witztum JL . Role of oxidized low density lipoprotein in atherogenesis. Br Heart J 1993;69:S12-s12.

56.

56. Vaarala O Puurunen M , Lukka M , et al. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Clin Exp Immunol 1996;104:269-269.

57.

57. Vaarala O Alfithan G , Jauhiainen M , et al. Cross-reaction between antibodies to oxidised lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341:923-923.

58.

58. Puruunen M , Manttari M , Manninen V , et al. Antibodies against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154:2605-2605.

59.

59. Vaarala O Puurunen M , Manttari M , et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996;75:456-456.

60.

60. Paterson A , Timperley W , Slater D . Coagulation abnormalities in fatal cerebral lupus erythematosus. J Royal Soc Med 1981;74:53-53.

61.

61. Hart RG , Miller VT , Coull BM . Cerebral infarction associated with lupus anticoagulant. ZD Preliminary report. Stroke 1984;15(1):114-114.

62.

62. Persson J , Stavenow L , Wikstrand J , et al. Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size. Arterioscler Thromb 1992;12:261-261.

63.

63. Geromlakos G , Domjan J . Ultrasonic carotid artery plaque structure and the risk of cerebral infarction on computed tomography. J Vasc Surg 1994;20:263-263.

64.

64. Hillen T , Niecza R , Munzberg H , et al. Carotid atherosclerosis, vascular risk profile and mortality in a population based sample of functionally healthy elderly subjects: The Berlin ageing study. J Intern Med 2000;247:679-679.

65.

65. Khouriy Z , Schwartz R , Gottlieb S , et al. Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid and femoral arteries evaluated by ultrasound. Am J Cardiol 1997;80:1429-1429.